1Department of Systems Immunology, College of Biomedical Science and the Institute of Bioscience and Biotechnology, Kangwon National University, Chuncheon, Korea.
2Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
3Department of New Biology, Daegu Gyeongbuk Institute of Science and Technology and Institute for Basic Science, Daegu, Korea.
4Molecular Medicine and Biopharmaceutical Sciences, Seoul National University College of Medicine and Pharmacy, Seoul, Korea.
5Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
Copyright © 2016 Korean Diabetes Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.
EEF1A1-AAb, eukaryote translation elongation factor 1 alpha 1 autoantibody; UBE2L3-AAb, ubiquitin-conjugating enzyme 2L3 autoantibody; T1DM, type 1 diabetes mellitus.
aReference range 1 was estimated from the total control subject sample (upper cutoff value was 1.418 for EEF1A1-AAb), bReference range 2 was estimated from control subjects <40 years old (upper cutoff value was 1.595 for EEF1A1-AAb), cReference range 1 was estimated from the total control subject sample (upper cutoff value was 2.512 for UBE2L3-AAb), dReference range 2 was estimated from control subjects <40 years old (upper cutoff value was 2.643 for UBE2L3-AAb), eDifference in the prevalence of autoantibodies according to age group using linear-by-linear association analysis.
Variable | No. (men %) | EEF1A1-AAb, % (number) | UBE2L3-AAb, % (number) | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Reference range 1a | Reference range 2b | Reference range 1c | Reference range 2d | |||||||
Control | T1DM | Control | T1DM | Control | T1DM | Control | T1DM | Control | T1DM | |
Age, yr | ||||||||||
18–29 | 30 (46.7) | 49 (53.1) | 6.7 (2/30) | 30.6 (15/49) | 3.3 (1/30) | 18.4 (9/49) | 6.7 (2/30) | 22.4 (11/49) | 3.3 (1/30) | 16.3 (8/49) |
30–39 | 60 (51.7) | 28 (39.3) | 3.3 (2/60) | 3.6 (1/28) | 1.7 (1/60) | 0 | 3.3 (2/60) | 0 | 3.3 (2/60) | 0 |
40–49 | 20 (50.0) | 16 (68.8) | 5.0 (1/20) | 0 | 5 (1/20) | 0 | 5.0 (1/20) | 0 | 0 | 0 |
50–59 | 20 (50.0) | 6 (66.7) | 0 | 0 | 0 | 0 | 5.0 (1/20) | 0 | 5.0 (1/20) | 0 |
60–69 | 20 (50.0) | 2 (0.0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
P for trendse | - | - | 0.615 | 0.001 | 0.423 | 0.009 | 0.409 | 0.003 | 0.588 | 0.014 |
EEF1A1-AAb, eukaryote translation elongation factor 1 alpha 1 autoantibody; UBE2L3-AAb, ubiquitin-conjugating enzyme 2L3 autoantibody; T1DM, type 1 diabetes mellitus. aReference range 1 was estimated from the total control subject sample (upper cutoff value was 1.418 for EEF1A1-AAb), bReference range 2 was estimated from control subjects <40 years old (upper cutoff value was 1.595 for EEF1A1-AAb), cReference range 1 was estimated from the total control subject sample (upper cutoff value was 2.512 for UBE2L3-AAb), dReference range 2 was estimated from control subjects <40 years old (upper cutoff value was 2.643 for UBE2L3-AAb), eDifference in the prevalence of autoantibodies according to age group using linear-by-linear association analysis.